Perspective Therapeutics financials
$2.62+4.80%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $884.0K | $1.5M | $1.4M |
| Gross profit | $884.0K | $1.5M | $1.4M |
| Gross margin | 100.0% | 100.0% | 100.0% |
| Operating income | -$113.6M | -$90.9M | -$40.9M |
| Net income | -$103.1M | -$79.3M | -$46.5M |
| Net margin | −11665.3% | −5452.5% | −3243.2% |
| Diluted EPS | $-1.40 | $-1.23 | $-1.74 |
| EBITDA | -$110.3M | -$64.5M | -$40.0M |
| Operating cash flow | -$82.5M | -$18.3M | -$36.9M |
| Free cash flow | -$95.4M | -$72.8M | -$38.0M |
| Diluted shares | 73.8M | 64.4M | 26.8M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $30.6M | $61.6M | $9.2M |
| Short-term investments | $114.1M | $165.3M | $0.00 |
| Total debt | $1.6M | $1.7M | $1.7M |
| Total assets | $267.0M | $341.1M | $97.9M |
| Total liabilities | $59.9M | $50.4M | $22.7M |
| Shareholders' equity | $207.0M | $290.7M | $75.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology